In this secondary analysis of the ECOG-ACRIN E2906 study, researchers assessed vulnerabilities of AML patients aged 60 years or older and their affect on survival outcomes.
AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...
1d
Blood Cancer United Expands its Beat AML® Master Clinical Trial Advancing Next-Generation Treatment
Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment ...
The combination therapy, referred to as DAGO+m, yielded a 91% overall response rate and a promising 2-year overall survival ...
The researchers suggest certain refinements to the 2022 European LeukemiaNet classification model for patients aged 60 years or older receiving lower intensity treatment (LIT), including the adoption ...
A DNA aptamer nanostructure enables targeted doxorubicin delivery to AML cells, improving treatment efficacy and safety, ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, enhancing treatment efficacy and inducing programmed cell death. The novel therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback